Search

Pharmaceutical analysis is a discipline based on chemical, physical, biological, and information technologies. At present, biotechnological analysis is a short branch in pharmaceutical analysis; however, bioanalysis is the basis and an important part of medicine. Biotechnological approaches can provide information on biological activity and even clinical efficacy and safety, which are important characteristics of drug quality. Because of their advantages in reflecting the overall biological effects or functions of drugs and providing visual and intuitive results, some biotechnological analysis methods have been gradually applied to pharmaceutical analysis from raw material to manufacturing and final product analysis, including DNA super-barcoding, DNA-based rapid detection, multiplex ligation-dependent probe amplification, hyperspectral imaging combined with artificial intelligence, 3D biologically printed organoids, omics-based artificial intelligence, microfluidic chips, organ-on-a-chip, signal transduction pathway-related reporter gene assays, and the zebrafish thrombosis model. The applications of these emerging biotechniques in pharmaceutical analysis have been discussed in this review. Pharmaceutical analysis (PA) is a discipline dominant by chemical and physical technologies, with week role of biological and information technologies. Here, the applications of emerging biotechnologies in PA are reviewed. [Display omitted] [ABSTRACT FROM AUTHOR]

Background The traditional herbal compound Danggui Buxue decoction (DBD), has long been used for the prevention and treatment of cardiovascular diseases, however, the underlying molecular mechanism for its effect remains still unknown. So this study would to investigate the effect of DBD on cardiac damage induced by myocardial infarction (MI) challenge. Methods SD Rats with ligation of left anterior descending (LAD) coronary artery were randomly divided into MI, MI plus Betaloc Zok, MI plus DBD high dose, and MI plus DBD low dose group, together with sham-operated group. After corresponding treatment for consecutive 4 weeks, cardiac function was evaluated by hemodynamics with the method of pressure-volume conduit system. Cardiac histological morphology, microvascular density and the expressions of VEGF and VEGFR 1/2 mRNA and their relative protein including VEGF, membranous VEGFR 1 (VEGFR 1 ), soluble VEGFR 1 (sVEGFR 1 ), VEGFR 2 , and sVEGFR 2 were examined by hematoxylin & eosin staining, immunohistochemical staining and quantitative polymerase chain reaction and western blot assay, respectively. Results It showed that a significant impaired cardiac function and a remarkably inducible increase in fibrotic scar formation, microvascular density and VEGF mRNA expressions in MI rats. While DBD treatment could markedly boost cardiac angiogenesis further, hinder fibrotic scar formation, and improve declined cardiac function. Apart from the up-regulation of VEGF mRNA and VEGF and the down-regulation of sVEGFR 1/2 , high dose of DBD dedicated to increasing VEGFR 1 mRNA and VEGFR 1 expression, while low dose to elevating VEGFR 2 mRNA and VEGFR 2 expression. Conclusion The present study demonstrated that DBD could accelerate cardiac angiogenesis, restrain fibrous scar formation and thus ameliorate cardiac function in post-MI, via the active regulation of VEGF/VEGFRs signaling pathway. [ABSTRACT FROM AUTHOR]